Japan Onychomycosis Market Size & Outlook, 2023-2030
Japan onychomycosis market, 2018-2030 (US$M)
Related Markets
Japan onychomycosis market highlights
- The Japan onychomycosis market generated a revenue of USD 225.2 million in 2023 and is expected to reach USD 311.0 million by 2030.
- The Japan market is expected to grow at a CAGR of 4.7% from 2024 to 2030.
- In terms of segment, topical was the largest revenue generating treatment in 2023.
- Topical is the most lucrative treatment segment registering the fastest growth during the forecast period.
Onychomycosis market data book summary
| Market revenue in 2023 | USD 225.2 million |
| Market revenue in 2030 | USD 311.0 million |
| Growth rate | 4.7% (CAGR from 2023 to 2030) |
| Largest segment | Topical |
| Fastest growing segment | Topical |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Oral, Topical |
| Key market players worldwide | GSK PLC, Abbott Laboratories, Pfizer Inc, Bausch Health Companies Inc, Bayer AG, Teva Pharmaceutical Industries Ltd, Cipla Ltd DR, Merck & Co Inc, Novartis AG ADR, Sun Pharmaceutical Industries |
Other key industry trends
- In terms of revenue, Japan accounted for 6.4% of the global onychomycosis market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China onychomycosis market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 374.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Onychomycosis Market Scope
Onychomycosis Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan onychomycosis market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to onychomycosis market will help companies and investors design strategic landscapes.
Topical was the largest segment with a revenue share of 57.64% in 2023. Horizon Databook has segmented the Japan onychomycosis market based on oral, topical covering the revenue growth of each sub-segment from 2018 to 2030.
In Japan, the onychomycosis market is expected to significantly grow owing to the rising geriatric population coupled with the rising focus of key players on developing and commercializing novel therapeutics.
Industry participants operating in Japan are launching novel solutions to treat onychomycosis. They are also focusing on gaining approvals from the country's regulatory body. For instance, in July 2018, Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. introduced NAILIN Capsules, an oral antifungal agent in Japan.
In addition, Sato Pharmaceutical Co., Ltd. received marketing and manufacturing approval for NAILIN Capsules for treating onychomycosis in Japan in January 2018. Such approvals and product launches are expected to boost the country's market over the forecast period.
Reasons to subscribe to Japan onychomycosis market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan onychomycosis market databook
-
Our clientele includes a mix of onychomycosis market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan onychomycosis market , including forecasts for subscribers. This country databook contains high-level insights into Japan onychomycosis market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Japan onychomycosis market size, by treatment, 2018-2030 (US$M)
Japan Onychomycosis Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
